FOS and neoplasm: Oliver H. Krämer and Günter Schneider reviewed the potential of combining c-FOS and HDAC inhibitors (HDACi) in DLBCL, noting that this combined strategy might enhance anti-tumor efficacy through the modulation of epigenetic modifications (51).